The radioenhancer NBTXR3: bridging physics and biology to improve radiotherapy outcomes and prime anti-tumor immunity.

J Exp Clin Cancer Res · 2025 · PMC12709859 · PMID 41408568

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

For CD4 + cells, only the irradiated tumors showed a noticeable change compared to control groups, with no significant difference between RT and NBTXR3 + RT, although NBTXR3 + RT showed a slight trend of increase.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.